NOTE F13 Other non-operating and non-cash items
- 12 NOTE F12 Depreciation, amortization and impairments
- 13 NOTE F13 Other non-operating and non-cash items
- 14 NOTEF14 Income taxes
- 15 NOTE F15 Changes in working capital
- 16 NOTE F16 Changes in provisions
- 17 NOTE F17 Cash flows from investing activities – acquisition/disposal of assets and investments
- 18 NOTE F18 Equity
- 19 NOTE F19 Other cash flows from financing activities
- 20 NOTE F20 Cash flow from discontinued operations
The other non-operating and non-cash items for 2017 (€(179) million) comprise mainly the result related to the disposal of Acetow (€(180) million), Cross Linkable Compound (€(43) million), Emerging Biochemicals (€(23) million), and the loss related to the deconsolidation of the Venezuelan subsidiary (€72 million).
The other non-operating and non-cash items for 2016 (€(16) million) comprise mainly the gain related to the reversal of the Chemlogics holdback (€(49) million), the impact from reversals of tax litigations provisions (€24 million), and other non-cash losses (impairment and gains on disposals).